Showing 4371-4380 of 8129 results for "".
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An
- Molluscum Contagiosum Update: Two New Treatments Come Down the Pikehttps://practicaldermatology.com/news/molluscum-contagiosum-update-two-new-treatments-come-down-the-pike/2461621/Thanks to a busy pipeline, treating molluscum contagiosum may get easier. The U.S. Food and Drug Administration (FDA) accepted Novan’s New Drug Application (NDA) for Berdazimer Gel, 10.3% for the treatment of molluscum contagiosum with a Prescription Drug User Fee A
- Dermatologist Terrence A. Cronin Jr., MD, Named New AAD Presidenthttps://practicaldermatology.com/news/dermatologist-terrence-a-cronin-jr-md-named-new-aad-president/2461615/Terrence A. Cronin Jr., MD, FAAD, is the new President of the American Academy of Dermatology. He will start his one-year term at the close of the Academy's Annual Meeting. Dr. Cronin will also hold the same position for the American Academy of Dermatology Association, a sister
- Guselkumab Shows Greater Treatment Persistence than IL-17s in Both Bio-naïve and Bio-experienced Psoriasis Patientshttps://practicaldermatology.com/news/guselkumab-shows-greater-treatment-persistence-than-il-17s-in-both-bio-naive-and-bio-experienced-psoriasis-patients/2461613/Tremyfa (guselkumab) may beat out other biologics when it comes to patient persistence, and a post-hoc analysis of guselkumab showed improvements in scalp psoriasis and quality-of-life measures at week 48. Research found that bio-experienced and bio-naïve psoria
- Bioelectric V.Dox Technology Reduces Biofilm Infection in Burn Woundshttps://practicaldermatology.com/news/bioelectric-vdox-technology-reduces-biofilm-infection-in-burn-wounds/2461611/Vomaris Innovations, Inc. bioelectric V.Dox Technology prevents and reduces biofilm infection in burn wounds, a new study shows. The study appears in Advances in Wound Care. The collaborative research was led by Rodney Chan, M.D, a plastic and reco
- LEO Pharma Adds to Global Leadership Teamhttps://practicaldermatology.com/news/leo-pharma-adds-to-global-leadership-team/2461607/Dr. Jacob Pontoppidan Thyssen is the new Executive Vice President and Chief Scientific Officer for LEO Pharma’s Research and Early Development arm. The company announced that a significant shift in R&D to a research model in early 2023. The change aims to drive the early-stage
- Cutera Updates truBody Brandhttps://practicaldermatology.com/news/cutera-updates-trubody-brand/2461605/Cutera has launched an updated truBody brand that pairs two technologies designed to create a customized, convenient, and complete approach to fat reduction and muscle toning with 15-minute treatment options, according to a company news release. The new truBody brand elevates both pract
- Long-term, Systemic Antibiotic Use for Teen Acne May Promote Fat Accumulationhttps://practicaldermatology.com/news/long-term-systemic-antibiotic-use-for-teen-acne-may-promote-fat-accumulation/2461603/Long-term antibiotic use for the treatment of adolescent acne disrupts the healthy gut microbiome, leading to changes in liver metabolism that promotes the accumulation of central fat, a new study shows. Around 25 percent of adolescents require systemic antibiotics, such as minocycline,
- Ribon Therapeutics: First Patient Dosed in Phase 1 Study with RBN-3143 of ADhttps://practicaldermatology.com/news/ribon-therapeutics-first-patient-dosed-in-phase-1-study-with-rbn-3143-of-ad/2461599/Ribon Therapeutics dosed the first patient with RBN-3143 in the open-label cohort of patients with moderate-to-severe atopic dermatitis. The study aims to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in
- National Society for Cutaneous Medicine Endorses Use of GEP Testing for Melanomahttps://practicaldermatology.com/news/national-society-for-cutaneous-medicine-endorses-use-of-gep-testing-for-melanoma/2461597/The National Society for Cutaneous Medicine now recommends use of gene expression profile (GEP) testing in the clinical assessment and management of cutaneous melanoma (CM). The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM